On April 1, 2026, Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company focused on developing novel oral therapies for neurologic diseases, announced that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price for continued listing. The company received a written notification from Nasdaq on March 27, 2026, confirming that its common stock maintained a minimum closing bid price of at least $1.00 per share for 20 consecutive business days, from February 27, 2026, to March 26, 2026. This compliance matter is now closed, allowing Immunic to continue its listing on the Nasdaq Capital Market without interruption. The company issued a press release detailing this development, which is expected to positively influence investor confidence and stabilize its stock price. Immunic's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, with top-line data anticipated by the end of 2026. This news is seen as a positive step for the company, as it alleviates concerns regarding its listing status and reflects its ongoing efforts to meet regulatory requirements. Investors and stakeholders are encouraged to monitor Immunic's progress as it continues to advance its clinical programs and navigate the complexities of the biotechnology sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.